首页> 外国专利> METHOD FOR PREDICTING THE NEED FOR ALLOGENEIC ERYTHROCYTE-CONTAINING BLOOD COMPONENTS IN PLANNED CARDIOSURGICAL INTERVENTIONS IN ADULT PATIENTS IN INTRAOPERATIVE AND EARLY POSTOPERATIVE PERIODS

METHOD FOR PREDICTING THE NEED FOR ALLOGENEIC ERYTHROCYTE-CONTAINING BLOOD COMPONENTS IN PLANNED CARDIOSURGICAL INTERVENTIONS IN ADULT PATIENTS IN INTRAOPERATIVE AND EARLY POSTOPERATIVE PERIODS

机译:预测术中和术后早期成人患者心律手术中异种含红细胞血成分的需要的方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to transfusiology, and is intended for use in medical institutions when predicting the need for allogeneic erythrocyte-containing blood components in the intraoperative and early postoperative periods with planned cardiosurgical interventions in adult patients. Essence of the method: on the eve of the operational day, on the basis of the plan of operations, when identifying the factors influencing the transfusion of allogeneic erythrocyte-containing blood components in the patient, they are assigned prognostic factors, namely to: valve prosthetics, with the exception of aortic valve, – 2 points, aortic valve prosthetics – 3 points, valve plastic – 1 point, surgery of aortic aneurysm – 5 points, surgery for congenital heart disease, with the exception of surgery on the valves of the heart, – 1 point, and at a combination of various kinds of operative intervention for calculation the highest ball increased by 1 unit, operations with artificial circulation – 1 point, age of the patient over 70 years old – 1 point, reoperation of the heart and aorta – 1 point, preoperative hemoglobin level 131–140 g/l – 1 point, preoperative hemoglobin level 121–130 g/l – 2 points, preoperative hemoglobin level 110–120 g/l – 3 points, preoperative hemoglobin level less than 110 g/l – 4 points , patient weight less than 70 kg – 1 point and with the sum of prognostic coefficients 0–2 points predict a minimal requirement and allogeneic erythrocyte-containing blood components on this patient do not reserve; with the sum of prognostic coefficients 3–4 points predict the need for a single dose of allogeneic erythrocyte-containing blood components; with the sum of prognostic coefficients of 5–7 points predict the need for 1.5 doses of allogeneic erythrocyte-containing blood components; with the sum of prognostic factors of 8–10 points predict the need for two doses of allogeneic erythrocyte-containing blood components; with the sum of prognostic factors of 11 points or more, predict the need for allogeneic erythrocyte-containing components of the blood more than two doses.;EFFECT: proposed invention is aimed at optimizing the operation of the transfusiology unit (blood transfusion unit) to form a stock of allogeneic erythrocyte-containing blood components by forecasting the need for them in the intraoperative and early postoperative periods in adult patients.;1 cl, 5 ex
机译:发明领域本发明涉及医学,即涉及超融合学(transfusiology),并且打算在成年患者通过计划的心脏外科手术干预来预测术中和术后早期对同种异体红细胞的血液成分的需求时,用于医疗机构。方法的实质:在手术当天的前夕,在手术计划的基础上,当确定影响患者体内含异基因红细胞血液成分输注的因素时,将它们分配为预后因素,即:假体,除主动脉瓣膜外– 2分,主动脉瓣膜假体– 3分,瓣膜整形– 1分,主动脉瘤手术– 5分,先天性心脏病手术,对瓣膜的手术除外心脏– 1分,结合各种手术干预进行计算,最高球增加1个单位,采用人工循环进行手术– 1分,年龄超过70岁的患者– 1分,心脏再手术主动脉– 1分,术前血红蛋白水平131–140 g / l – 1分,术前血红蛋白水平121–130 g / l – 2分,术前血红蛋白水平110–120 g / l – 3分,术前血红蛋白水平l低于110 g / l – 4分,患者体重低于70 kg – 1分,且预后系数总和为0–2分,预示最低需求,该患者的异体含红血球血液成分无法保留;预后系数的总和为3-4分可预测是否需要单剂量含异基因红细胞的血液成分;预后系数的总和为5–7分,可以预测需要1.5剂量的含异基因红细胞的血液成分;预后因素总和为8–10分,预测需要使用两剂含同种异体红细胞的血液成分;预后因素总和为11分或以上,预测血液中异基因含红细胞成分的需求量为两次以上;效果:拟议的发明旨在优化输血科(血液输注)的操作通过预测成年患者术中和术后早期对异体红细胞的血液成分的需求来形成储备; 1 cl,5 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号